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Sir,
It is with great interest that I read the article by Thompson Coon
et al, as I agree with the authors that there is a need for performing
indirect treatment comparisons in order to offer guidance on
therapy decisions to oncologists.
As this is an important topic, I would like to outline some methodo-
logical issues that are related to the Thompson Coon et al analysis.
P-VALUE CALCULATION APPROACH
Using a one-sided t-test to calculate a P-value, as performed by
Thompson Coon et al (2009), has to be regarded as a questionable
approach, as two-sided t-tests are the common approach in clinical
research and should be expected in such an analysis by the clinical
readers of BJC. Even if this unusual approach is explicitly described,
the findings in the abstract are misleading, as they seem to show
statistical proof on a significant difference comparing sunitinib
(SUN) with bevacizumab (BEV)þ interferon alpha-2a (IFN) in first-
line metastatic renal cell carcinoma. To elaborate, Thompson Coon
et al (2009) simply calculated the P-value as the proportion of
Bayesian Markov Chain Monte-Carlo (MCNC) trials in which the
hazard ratio (HR) for any comparison exceeded the indirect
comparison HR of ‘1’. In contrast, the authors should have reported
the number of instances in which the lower confidence limit of HR
for each iteration exceeded 1 or simply tested the hypothesis that
Log(HR)¼ 0, using the standard z-statistic. If a valid statistical
method is used (e.g., that from Snedecor and Cochran, 1989), this
would have led to a P-value that indicates a non-significant
difference between SUN and BEVþ IFN. This non-significant
difference between both therapy options using a two-sided t-test is
obvious, as the indirect comparison HR of SUN vs BEVþ IFN
exceeded ‘1’ in the upper 95% confidence interval limit.
MCMC SAMPLING
The authors performed an indirect comparison using Bayesian
MCMC sampling, with IFN as a common comparator, adopting a
fixed-effect model. Point estimates and 95% confidence intervals
were calculated from 100 000 simulated draws from the posterior
distribution after a burn-in of 10 000 iterations.
This up-sampling of point estimates has most likely led
to more narrow confidence intervals that may be responsible
for possible significant differences between treatments. Taking
into account the fact that the SUN pivotal trial included
750 patients (Motzer et al, 2007) and the pooled BEV trials
included 1381 patients (Escudier et al, 2007; Rini et al, 2008),
the chosen number of simulation samples overpowers that
of base trials. In general, it is recommended to either select
the number of iterations on the total number of patients or
the expected number of patients in the country of interest;
hence, around 2000 simulation samples would have been an
appropriate choice.
INDIRECT COMPARISON APPROACH
Although the authors name the Bucher et al methodology (Bucher
et al, 1997) as ‘a fairly simple analytical approach’, the Canadian
Agency for Drugs and Technologies in Health (CADTH) (Wells
et al, 2009a) and others (Tudur et al, 2002; Song et al, 2003) have
identified this method as the most suitable approach for
performing indirect treatment comparisons. The Bucher et al
methodology is to be regarded as the gold-standard method for
indirect treatment comparisons, as it is transparent and excludes
the risk of producing misleading results that may be produced by
up-sampling the power of base trials.
BASE DATA USED
An adequate indirect comparison approach should consider
pivotal trials performed under similar conditions as comparable,
and assume highest data quality (independent radiology review of
PFS, blinded as opposed to the open-label study).
If the author pooled a pivotal trial (Escudier et al, 2007) and an
investigator-initiated trial (Rini et al, 2008) for BEVþ IFN, the
same approach should have been applied for SUN using the pivotal
trial (Motzer et al, 2007) and first-line outcomes from the
expanded access study (Gore et al, 2007).
OWN FINDINGS
According to our own ongoing research that uses the gold-standard
Bucher et al methodology and an independent review PFS HR of*Correspondence: Dr M Nuijten; E-mail: nuijten@bmg.eur.nl
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pivotal trials (SUN vs IFN 0.538; 95% CI: 0.439–0.658 (Motzer
et al, 2007), BEVþ IFN vs IFN 0.571 (0.450–0.723) (Escudier et al,
2009)), there is no statistically significant evidence for a difference
in efficacy with respect to PFS between SUN and BEVþ IFN-a. The
indirect comparison HR was 0.942 (95% CI 0.69–1.29; two-sided
t-test P¼ 0.71).
CADTH offers an open-access tool (Wells et al, 2009b) that enables
researchers worldwide to re-perform and validate our findings.
As indirect treatment comparisons are increasingly used in
medical decision making, I considered it important to draw
attention to methodological issues for the benefit of those both
performing and using the results of these comparisons.
REFERENCES
Bucher HC, Guyatt GH, Griffith LE, Walter SD (1997) The results of direct
and indirect treatment comparisons in meta-analysis of randomized
controlled trials. J Clin Oncol, 2009 ASCO Annual Meeting Proceedings.
Vol. 27, No. 15s: Abstract no. 5020
Escudier B, Bellmunt J, Negrier S, Melichar B, Bracarda S, Ravaud A,
Golding S, Jethwa S (2009) Final results of the phase III, randomized,
double-blind AVOREN trial of first-line bevacizumab (BEV) + inter-
feron-alpha-2a (IFN) in metastatic renal cell carcinoma (mRCC). J Clin
Oncol, 2009 ASCO Annual Meeting Proceedings. Vol. 27, No. 15S:
Abstract no. 5020
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C,
Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO,
Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus
interferon alfa-2a for treatment of metastatic renal cell carcinoma: a
randomised, double-blind phase III trial. Lancet 370: 2103–2111
Gore ME, Porta C, Oudard S, Bjarnason G, Castellano D, Szczylik C,
Mainwaring PN, Scho¨ffski P, Rini BI, Bukowski M (2007) Sunitinib in
metastatic renal cell carcinoma (mRCC): preliminary assessment of
toxicity in an expanded access trial with subpopulation analysis. J Clin
Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25, No. 18S:
Abstract no. 5010
Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O,
Bjarnason GA, Kim ST, Chen I, Michaelson D (2007) Sunitinib versus
interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell
carcinoma (mRCC): updated results and analysis of prognostic factors.
J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol. 25,
No. 18S: Abstract no. 5024
Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L,
Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008)
Bevacizumab plus interferon alfa compared with interferon alfa
monotherapy in patients with metastatic renal cell carcinoma: CALGB
90206. J Clin Oncol 26: 5422–5428
Snedecor GW, Cochran WG (1989) Statistical Methods, 8th edn. Iowa State
University Press: Ames, Iowa State, USA
Song F, Altman DG, Glenny AM, Deeks JJ (2003) Validity of indirect
comparison for estimating efficacy of competing interventions: empirical
evidence from published meta-analyses. Br Med J 326: 472
Thompson Coon JS, Liu Z, Hoyle M, Rogers G, Green C, Moxham T,
Welch K, Stein K (2009) Sunitinib and bevacizumab for first-line
treatment of metastatic renal cell carcinoma: a systematic review and
indirect comparison of clinical effectiveness. Br J Cancer 101(2): 238–243
Tudur C, Williamson PR, Khan S, Best LY (2002) The value of the aggregate
data approach in meta-analysis with time-to-event outcomes. J R Stat Soc
164: 357–370
Wells GA, Sultan SA, Chen L, Khan M, Coyle D (2009a) Indirect Evidence:
Indirect Treatment Comparisons in Meta-Analysis. Canadian Agency for
Drugs and Technologies in Health: Ottawa
Wells GA, Sultan SA, Chen L, Khan M, Coyle D (2009b) Indirect Treatment
Comparison [computer program] Version 1.0. Canadian Agency for
Drugs and Technologies in Health: Ottawa
Letter to the Editor
233
British Journal of Cancer (2010) 102(1), 232 – 233& 2010 Cancer Research UK
